Abstract
Retinopathy of Prematurity (ROP) is a proliferative retinal vascular disease affecting the retina of premature infants and is considered the major cause of blindness in children and the most common cause of retinal vasculopathy in premature and in low-birth-weight infants. The clinical spectrum of ROP varies from spontaneous regression to bilateral retinal detachment and total blindness. Between these two extremes lies the form of ROP, which mandates treatment with laser photocoagulation, or surgery. Increasing rates of preterm births together with better survival rates but lack of efficient screening and delays in the diagnosis causes an increase in the ROP rate. In developing countries, the atypical form of aggressive posterior ROP was reported in the use of unblended oxygen of more mature infants. Prevention of ROP by following efficient protocols of supplemental oxygen, prevention of sepsis, timely screening, and laser treatment requiring coordinated teamwork between neonatologists and trained ophthalmologists are mandatory to prevent ROP.
Article PDF
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: I. Preliminary report. Am J Ophthalmol 1942;25:203–4.
Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, et al. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005;116:15–23.
Zin A, Gole GA. Retinopathy of prematurity-incidence today. Clin Perinatol 2013;40:185–200.
Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75–84.
Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, et al. International NO-ROP Group. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005;115:e518–e25.
Blencowe H, Lee AC, Cousens S, Bahalim A, Narwal R, Zhong N, et al. Preterm birth–associated neurodevelopmental impairment estimates at regional and global levels for 2010. Pediatr Res 2013;74:17–34.
Al-Amro SA, Al-Kharfi TM, Thabit AA, Al-Mofada SM. Retinopathy of prematurity at a university hospital in Riyadh, Saudi Arabia. Saudi Med J 2003;24:720–4.
Waheeb S, Alshehri K. Incidence of retinopathy of prematurity at two tertiary centers in Jeddah, Saudi Arabia. Saudi J Ophthalmol 2016;30:109–12.
Binkhathlan AA, Almahmoud LA, Saleh MJ, Srungeri S. Retinopathy of prematurity in Saudi Arabia: incidence, risk factors, and the applicability of current screening criteria. Br J Ophthalmol 2008;92:167–9.
Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med 2013;368:1162–3.
Jasani B, Nanavati R, Kabra N. Mechanisms and management of retinopathy of prematurity. N Engl J Med 2013;368:1161–2.
Rao RC, Dlouhy BJ. Mechanisms and management of retinopathy of prematurity. N Engl J Med 2013;368:1161.
Kushner BJ, Essner D, Cohen IJ, Flynn JT. Retrolental fibroplasia: II. Pathologic correlation. Arch Ophthalmol 1977;95:29–38.
Rivera JC, Sapieha P, Joyal JS, Duhamel F, Shao Z, Sitaras N, et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology 2011;100:343–53.
Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000;105:295–310.
Chen ML, Guo L, Smith LEH, Dammann CEL, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics 2010;125:e1483–e92.
Chen M, Çitil A, McCabe F, Leicht KM, Fiascone J, Dammann CEL, et al. Infection, oxygen, and immaturity: interacting risk factors for retinopathy of prematurity. Neonatology 2011;99:125–32.
Karna P, Muttineni J, Angell L, Karmaus W. Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr 2005;5:18.
Dutta S, Narang S, Narang A, Dogra M, Gupta A. Risk factors of threshold retinopathy of prematurity. Indian Pediatr 2004;41:665–71.
Brooks SE, Marcus DM, Gillis D, Pirie E, Johnson MH, Bhatia J. The effect of blood transfusion protocol on retinopathy of prematurity: a prospective, randomized study. Pediatrics 1999;104:514–18.
Fortes Filho JB, Bonomo PP, Maia M, Procianoy RS. Weight gain measured at 6 weeks after birth as a predictor for severe retinopathy of prematurity: study with 317 very low birth weight preterm babies. Graefe’s Arch Clin Exp Ophthalmol 2009;247:831–6.
Husain SM, Sinha AK, Bunce C, Arora P, Lopez W, Mun KS, et al. Relationships between maternal ethnicity, gestational age, birth weight, weight gain, and severe retinopathy of prematurity. J Pediatr 2013;163:67–72.
Shastry BS. Genetic susceptibility to advanced retinopathy of prematurity (ROP). J Biomed Sci 2010;17:69.
Leviton A, Dammann O, Engelke S, Allred E, Kuban KCK, O’Shea TM, et al. The clustering of disorders in infants born before the 28th week of gestation. Acta Paediatr 2010;99: 1795–800.
Farooqi A, Hägglöf B, Sedin G, Serenius F. Impact at age 11 years of major neonatal morbidities in children born extremely preterm. Pediatrics 2011;127:e1247–e57.
An international classification of retinopathy of prematurity. Pediatrics 1984;74:127–33.
International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991–9.
Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684–94.
Kleberg A, Warren I, Norman E, Mörelius E, Berg AC, Mat-Ali E, et al. Lower stress responses after newborn individualized developmental care and assessment program care during eye screening examinations for retinopathy of prematurity: a randomized study. Pediatrics 2008;121:e1267–e78.
Al Amro SA, Al Aql F, Al Hajar S, Al Dhibi H, Al Nemri A, Mousa A, et al. Practical guidelines for screening and treatment of retinopathy of prematurity in Saudi Arabia. Saudi J Ophthalmol 2018;32:222–6.
Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1988;106:471–9.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 2001;119:1110–8.
McNamara JA, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology 1991;98:576–80.
Hunter DG, Repka MX. Diode laser photocoagulation for threshold retinopathy of prematurity: a randomized study. Ophthalmology 1993;100:238–44.
Laser therapy for retinopathy of prematurity. Laser ROP Study Group. Arch Ophthalmol 1994;112:154–6.
Iverson DA, Trese MT, Orgel IK, Williams GA. Laser photocoagulation for threshold retinopathy of prematurity. Arch Ophthalmol 1991;109:1342–3.
Amro Saleh Al, Ahmad Adil M, Abu El Asrar AM. Laser photocoagulation for threshold retinopathy of prematurity. Saudi J Ophthalmol 1998;12:12–15.
Sanghi G, Dogra MR, Katoch D, Gupta A. Aggressive posterior retinopathy of prematurity: risk factors for retinal detachment despite confluent laser photocoagulation. Am J Ophthalmol 2013;155: 159.e2–64.e2.
Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28:831–8.
Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 2013;98:F170–F4.
Bhende P, Gopal L, Sharma T, Verma A, Biswas RK. Functional and anatomical outcomes after primary lens-sparing pars plana vitrectomy for stage 4 retinopathy of prematurity. Indian J Ophthalmol 2009;57:267–71.
Shah PK, Narendran V, Kalpana N, Tawansy KA. Anatomical and visual outcome of stages 4 and 5 retinopathy of prematurity. Eye (Lond) 2009;23:176–80.
Wright KW, Strube YN. Retinopathy of prematurity. Pediatric ophthalmology and strabismus. New York, NY: Oxford University Press; 2012, pp. 957–92.
Fierson WM. American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2014;131:189–95.
MacFarlane PM, Di Fiore JM. Myo-inositol effects on the developing respiratory neural control system. Adv Exp Med Biol 2018;1071: 159–66.
Du Y, He Y, Wang YL, Zhou JG, Chen C. The efficacy and safety of inositol supplementation in preterm infants to prevent retinopathy of prematurity: a systematic review and meta-analysis. BMC Ophthalmol 2019;19:135.
Rey-Funes M, Dorfman VB, Ibarra ME, Peña E, Contartese DS, Goldstein J, et al. Hypothermia prevents gliosis and angiogenesis development in an experimental model of ischemic proliferative retinopathy. Invest Ophthalmol Vis Sci 2013;54:2836–46.
Lyu Y, Shah PS, Ye XY, Warre R, Piedboeuf B, Deshpandey A, et al. Association between admission temperature and mortality and major morbidity in preterm infants born at fewer than 33 weeks’ gestation. JAMA Pediatr 2015;169:e150277.
Lunze K, Bloom DE, Jamison DT, Hamer DH. The global burden of neonatal hypothermia: systematic review of a major challenge for newborn survival. BMC Med 2013;11:24.
Reynolds JD, Hardy RJ, Kennedy KA, Spencer R, van Heuven WAJ, Fielder AR. Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group. New Engl J Med 1998;338:1572–6.
Soghier LM, Brion LP. Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates. Cochrane Database Syst Rev 2006;4:CD004869.
Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2003;4:CD003665.
Park TS, Bhutto I, Zimmerlin L, Huo JS, Nagaria P, Miller D, et al. Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature. Circulation 2014;129:359–72.
Darlow BA, Gilbert C. Retinopathy of prematurity – a world update. Semin Perinatol 2019;43:315–6.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the Dr. Sulaiman Al Habib Medical Services Group Company
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (https://doi.org/creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Al Rashaed, S. Retinopathy of Prematurity—A Brief Review. Dr. Sulaiman Al Habib Med J 1, 58–64 (2019). https://doi.org/10.2991/dsahmj.k.191214.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/dsahmj.k.191214.001